The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Novartis
Research Funding - Millennium
Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study.
 
Eytan M. Stein
Consulting or Advisory Role - Agios; Celgene; Novartis; Pfizer
Research Funding - Agios; Celgene; Constellation Pharmaceuticals; GlaxoSmithKline; Novartis; Seagen
Travel, Accommodations, Expenses - Celgene; Pfizer
 
Courtney Denton Dinardo
Honoraria - Agios; Daiichi Sankyo; Novartis
Research Funding - Abbvie; AGIOS; Celgene; Daiichi Sankyo; Novartis
 
Daniel Aaron Pollyea
Consulting or Advisory Role - Alexion Pharmaceuticals; Ariad; Celgene; Karyopharm Therapeutics; Pfizer
Research Funding - Celgene
 
Amir Tahmasb Fathi
Honoraria - Agios; Baxalta; Merck; Seagen; Tolero Pharmaceuticals
Research Funding - Celgene (Inst); Exelixis (Inst); Seagen (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Agios
 
Gail J. Roboz
Consulting or Advisory Role - Agios; Amgen; Amphivena; Astex Pharmaceuticals; AstraZeneca; Boehringer Ingelheim; Celator; Celgene; Cellectis; CTI; Genoptix; GlaxoSmithKline; Janssen; Juno Therapeutics; MedImmune; MEI Pharma; Novartis; Onconova Therapeutics; Pfizer; Roche; Shire; Sunesis Pharmaceuticals
Research Funding - Abbvie (Inst); Agios (Inst); Astex Pharmaceuticals (Inst); Celgene (Inst); Cellectis (Inst); CTI (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); MEI Pharma (Inst); Moffitt (Inst); Novartis (Inst); Onconova Therapeutics (Inst); Pfizer (Inst); Sunesis Pharmaceuticals (Inst); Tensha Therapeutics (Inst)
Travel, Accommodations, Expenses - Amphivena; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Celator; Incyte; Janssen; Juno Therapeutics; MEI Pharma; Roche; Shire
 
Jessica K. Altman
Consulting or Advisory Role - ASH; Astellas Oncology; Bristol-Myers Squibb; Celgene; Immune Pharmaceuticals; Janssen; NCCN; Syros Pharmaceuticals
Research Funding - Agios (Inst); Astellas Oncology (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Genentech (Inst)
 
Richard M. Stone
Consulting or Advisory Role - Abbvie; Agios; Amgen; Bristol-Myers Squibb; Celator; Celgene; Fujifilm; Juno Therapeutics; Karyopharm Therapeutics; Merck; Novartis; Ono Pharmaceutical; Roche/Genentech; Theradex
Research Funding - Agios (Inst); Celator (Inst); Karyopharm Therapeutics (Inst); Novartis (Inst)
 
Ian Flinn
Stock and Other Ownership Interests - RainTree Oncology Services
Research Funding - Acerta Pharma (Inst); Agios (Inst); Calithera Biosciences (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunogen (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Kite, a Gilead company (Inst); Medivation (Inst); Millennium (Inst); Novartis (Inst); OncoMed (Inst); Pharmacyclics (Inst); Portola Pharmaceuticals (Inst); Roche (Inst); Seagen (Inst); TG Therapeutics (Inst); Trillium Therapeutics (Inst)
 
Hagop M. Kantarjian
No Relationships to Disclose
 
Robert Collins
Honoraria - Dava Oncology; OptumHealth
Travel, Accommodations, Expenses - National Marrow Donor Program
 
Manish R. Patel
Honoraria - Bristol-Myers Squibb; Exelixis; Genentech; Gilead Sciences; Medivation
Consulting or Advisory Role - Guardant Health
Speakers' Bureau - Bristol-Myers Squibb; Exelixis; Genentech; Gilead Sciences; Medivation
 
Anthony Selwyn Stein
Consulting or Advisory Role - Amgen
Speakers' Bureau - Amgen
Research Funding - Agios; Amgen; Celgene; Seagen; Stemline Therapeutics
 
Mikkael A. Sekeres
Consulting or Advisory Role - Celgene; Millennium
 
Ronan T. Swords
No Relationships to Disclose
 
Bruno C. Medeiros
Honoraria - Celator; Celgene; Jazz Pharmaceuticals; Novartis
Consulting or Advisory Role - Astellas Oncology; Celator; Celgene; Genentech/Roche; Jazz Pharmaceuticals; Novartis
Research Funding - Agios; Astellas Oncology; Celator; Celgene; Novartis
Travel, Accommodations, Expenses - Celator; Celgene; Genentech/Roche; Novartis
 
Robert D. Knight
Employment - Celgene
Stock and Other Ownership Interests - Celgene
 
Samuel V. Agresta
Employment - Agios
Stock and Other Ownership Interests - Agios
Patents, Royalties, Other Intellectual Property - Agios
 
Stéphane de Botton
Consulting or Advisory Role - Agios; Celgene; Novartis
Research Funding - Agios
Travel, Accommodations, Expenses - Agios; Celgene
 
Martin S. Tallman
Honoraria - Danbury Hospital; Henry Ford Hospital; Lundbeck Canada; Mayo Clinic; New York Medical College; Onclive; Rush University; St Vincent's Hospital; University of Oklahoma
Research Funding - ADC Therapeutics; Arog; BioLineRx; Cellerant